Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
MEI Pharma, Inc.
Xenikos
SecuraBio
Gilead Sciences
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
Takeda
Hutchmed
Gilead Sciences
University of Nebraska
Pfizer
Pfizer
OHSU Knight Cancer Institute
CTI BioPharma
Fred Hutchinson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC